503A vs 503B pharmacies: what the difference actually means for your medication

There are two distinct sections of the US Federal Food, Drug, and Cosmetic Act that authorize compounding — section 503A and section 503B. They are very different.

A 503A pharmacy prepares patient-specific compounded medications. That means a licensed prescriber writes a prescription for an individual patient, and the pharmacy compounds that specific preparation for that specific person. 503A pharmacies are licensed by their state pharmacy board and operate under state oversight.

A 503B outsourcing facility is registered with the FDA (not just the state) and can prepare batches of compounded medications without patient-specific prescriptions. 503B facilities operate under cGMP-equivalent standards — the same quality framework as a small manufacturer — and are subject to FDA inspection.

Compounded semaglutide and tirzepatide can legally be prepared via either pathway, but the practical implications differ. 503A patient-specific compounding is more flexible (it can accommodate documented allergies, custom dosing, etc.) but operates under lighter oversight than 503B. 503B batch preparation is more standardized, with per-batch sterility and potency testing typical, but offers less individualization.

Neither pathway produces an FDA-approved drug product. A compounded GLP-1 from either a 503A or a 503B is not Wegovy, Zepbound, Ozempic, or Mounjaro — it is a separately-prepared preparation that happens to contain the same active ingredient. The brand-name versions go through FDA's drug-approval process; compounded preparations do not.

Reputable telehealth providers disclose, in writing: (1) which pathway your medication will be prepared under (503A, 503B, or either depending on the patient and dose), (2) the named pharmacy partner(s) they use, and (3) whether a certificate of analysis is available on request.

The certificate of analysis (CoA) is a per-batch document showing sterility testing (USP <71>), bacterial endotoxin testing (USP <85>), and potency analysis (typically by HPLC) for the specific batch your medication came from. If your provider can't or won't produce one on request, that's a meaningful negative signal.

Compounded GLP-1s are sometimes marketed as 'FDA-registered' because the 503B pathway involves FDA registration. That phrasing is accurate but easily misleading — the facility is FDA-registered, but the compounded preparation itself is not an FDA-approved drug product.

Similarly, some marketing implies that 503B preparations are 'the same as' brand-name product because both are cGMP-equivalent. They are not. The brand-name product is a specific, FDA-reviewed drug with documented bioequivalence, stability, and a specific labeled formulation. A 503B compounded preparation is a separately-produced preparation that the FDA has not reviewed or approved as a drug.

Three questions that produce more signal than almost any marketing copy:

1. Which pharmacy will dispense my medication, and is that pharmacy 503A, 503B, or both? 2. Can I see a certificate of analysis for the batch my medication is from, if I request one? 3. If FDA action changes the compounding landscape (e.g., a Bulks List change), what is the contingency for continuing my treatment?

A provider that can answer all three clearly is operating with a level of transparency that materially exceeds the industry median.